Navigation Links
Weight-Loss Medication Evaluated By Nutrition Expert

A 60 mg low-dose version of the prescription weight-loss medication orlistat (marketed by GlaxoSmithKline as Xenical? 120 mg) was found to be safe, effective and tolerable in overweight individuals,// according to new data presented today at the 2005 Annual Meeting of NAASO, The Obesity Society in Vancouver, British Columbia.

The study, which compared orlistat 60 mg plus diet to placebo plus diet in patients with a body mass index (BMI) of 25 to 28, demonstrates a statistically significant difference in weight loss. Orlistat patients who completed the four-month treatment period lost 5 percent of their baseline weight and diet alone lost 3.3 percent.

The randomized, placebo-controlled, 16-week study was conducted in a primary care setting, offered minimal intervention and was largely self-instructional. Approximately 36 percent of orlistat users and 28 percent of the placebo group (who used diet modifications alone) lost more than five percent of their initial body weight. Approximately 57 percent of orlistat users, compared to 42 percent of the placebo group, lost more than three percent of their initial body weight.

Orlistat patients also demonstrated significant decreases in total cholesterol, LDL cholesterol, systolic and diastolic blood pressure. Safety and tolerability of 60 mg orlistat in this population was similar to that observed in previous studies in a more overweight population.

"Prescription orlistat has been used successfully for years to help obese individuals lose weight and improve their health, so it's exciting to find that a lower dose of orlistat can help those who are overweight with their weight loss efforts," said lead investigator Dr. James Anderson, Professor of Medicine and Clinical Nutrition at the University of Kentucky. "The number of overweight individuals in this country continues to increase each year, and the risk of these folks progressing to obesity - and the resulting more serious med ical problems - is significant."
'"/>




Related medicine news :

1. Weight-Loss Drinks Can Make You Gassy
2. Weight-Loss Surgeries Changing Lives
3. Latest Weight-Loss Pill Offers Modest Results, Blocks Munchies
4. Weight-Loss Drugs – Will They also Make You Lose Sleep
5. What happens when Medications go wrong?
6. Medications to Prevent Relapse to Cocaine Use
7. More Elderly Take Inappropriate and Harmful Medications
8. Medications for depression
9. Medications linked to xerostomia and caries
10. Medication recuperates fat distribution in diabetes
11. Pharmacist’s Role in Medication Error
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2017)... ... January 23, 2017 , ... ... new plugin that allows sleep centers to automatically connect and initialize all their ... thin client browser plugin is quickly installed on first use and then monitors ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... website this week at a new domain address. Alpine Springs Rehabilitation & Recovery ... has also debuted a new logo along with its redesigned and retooled website. ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... life science companies, has achieved ISO 17100:2015 certification following a comprehensive audit ... is the globally recognized standard that establishes guidance for critical processes within ...
(Date:1/23/2017)... ... January 23, 2017 , ... DMG Productions is ... Ed Begley, Jr., scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , ... in 2008 to address the limitations of fatigue monitoring technologies within the mining ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... Wooden and plastic balance boards have been ... and improve balance. Kumo Board is the first and only balance board to ... to be soft and rigid at the same time as well as skill-level adjustable for ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Research and Markets has announced the addition of the ... their offering. ... The interventional radiology products market is expected to reach USD 8.02 ... CAGR of 4.8%. This market is segmented based on type, procedure, ... of this market are rising incidence of chronic diseases, rising geriatric ...
(Date:1/23/2017)... 23, 2017  Delcath Systems, Inc. (NASDAQ: ... treatment of primary and metastatic liver cancers, today announced ... President and Chief Executive Officer of Delcath will be ... Markets, Thirteenth Annual Investor Conference at the Boca Raton ... , on Tuesday, January 31, 2017 at 10:30 ...
(Date:1/23/2017)... , January 23, 2017 ... (r enal) y el riesgo ... de a pabetalone    Resverlogix Corp. ... resultados preliminares de un ensayo en fase 1 con ... de riñón (renal) severa. Los datos demostraron unos resultados ...
Breaking Medicine Technology: